<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Glucagon: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Glucagon: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Glucagon: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11376" href="/d/html/11376.html" rel="external">see "Glucagon: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13335" href="/d/html/13335.html" rel="external">see "Glucagon: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F176479"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Baqsimi One Pack;</li>
<li>Baqsimi Two Pack;</li>
<li>GlucaGen Diagnostic;</li>
<li>GlucaGen HypoKit;</li>
<li>Gvoke HypoPen 1-Pack;</li>
<li>Gvoke HypoPen 2-Pack;</li>
<li>Gvoke Kit;</li>
<li>Gvoke PFS</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867058"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Baqsimi;</li>
<li>GlucaGen;</li>
<li>GlucaGen HypoKit</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F176511"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antidote;</li>
<li>
                        Antidote, Hypoglycemia;</li>
<li>
                        Diagnostic Agent</li></ul></div>
<div class="block doa drugH1Div" id="F176481"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8b597bee-38b4-4f8d-a59f-a1484390de69">Anaphylaxis in patients on beta-blocker therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anaphylaxis (refractory to epinephrine) in patients on beta-blocker therapy (off-label use):</b>
<b>IV:</b> Initial: 1 to 5 mg bolus; followed by an infusion of 5 to 15 <b>mcg/minute</b>; titrate the infusion rate to achieve an adequate clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26505932']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26505932'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d5914c62-3220-46b2-be0c-d96b19443139">Beta-blocker overdose</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Beta-blocker overdose (off-label use):</b>
<b>IV:</b> 3 to 10 mg bolus; if no clinical response may repeat bolus dose; if clinical response with bolus, start continuous infusion at 3 to 5 mg/hour; titrate infusion rate to achieve adequate hemodynamic response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30412709','lexi-content-ref-20956228','lexi-content-ref-Barrueto.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30412709','lexi-content-ref-20956228','lexi-content-ref-Barrueto.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c249f3aa-2980-4cf2-b10a-11628f338aea">Calcium channel blocker overdose</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Calcium channel blocker overdose (off-label use): IV:</b> 3 to 10 mg bolus; if no clinical response may repeat bolus dose; if clinical response with bolus, start continuous infusion at 3 to 5 mg/hour; titrate infusion rate to achieve adequate hemodynamic response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30412709','lexi-content-ref-Barrueto.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30412709','lexi-content-ref-Barrueto.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b0baab8d-8f30-4be0-bcd7-dcdb2a8ff408">Diagnostic aid, radiologic examinations</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diagnostic aid, radiologic examinations:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Relaxation of colon:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IM:</b> 2 mg.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Relaxation of duodenal bulb, duodenum, and small bowel:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IM:</b> Usual dose: 1 mg; may give up to 2 mg if needed.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> Usual dose: 0.25 to 0.5 mg; may give up to 2 mg if needed.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Relaxation of stomach:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IM:</b> 2 mg.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 0.5 mg; may give up to 2 mg if needed.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="24fbb6ce-c170-4924-a157-da41caba5aa4">Growth hormone deficiency, alternative diagnostic test</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Growth hormone deficiency, alternative diagnostic test (off-label use): Note:</b> Correct other pituitary hormone deficiencies prior to administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31760824','lexi-content-ref-26897383']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31760824','lexi-content-ref-26897383'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Weight ≤90 kg: 1 mg as a single dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Weight &gt;90 kg: 1.5 mg as a single dose.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cae6678c-7f9f-417f-b0d5-a66ff7ecfced">Hypoglycemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypoglycemia:</b>
<b>Note:</b> IV dextrose should be administered as soon as it is available; if patient fails to respond to glucagon, IV dextrose must be given.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Injection:</b></p>
<p style="text-indent:-2em;margin-left:6em;">GlucaGen HypoKit or Glucagon Emergency: <b>IM, IV, SUBQ:</b> 1 mg; may repeat in 15 minutes as needed.</p>
<p style="text-indent:-2em;margin-left:6em;">Gvoke:<b> SUBQ:</b> 1 mg; may repeat in 15 minutes as needed using a new device.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Intranasal:</b> 3 mg (one actuation) into a single nostril; if no response, may repeat in 15 minutes using a new intranasal device.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991850"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50989145"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F176482"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F176497"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13335" href="/d/html/13335.html" rel="external">see "Glucagon: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6fe33f22-06d5-4e9d-a446-d6156c0d716c">Hypoglycemia, severe; treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypoglycemia, severe; treatment: Note:</b> Glucagon should be prescribed for all type 1 diabetic patients and type 2 diabetic patients at increased risk of level 2 (&lt;54 mg/dL) or level 3 hypoglycemia; caregivers, school personnel, and family members of these patients should be trained on when and how to administer glucagon (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.1','lexi-content-ref-30093549']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.1','lexi-content-ref-30093549'])">Ref</a></span>). Patients with inadequate glycogen stores (eg, starvation, adrenal insufficiency, chronic hypoglycemia) may not respond to glucagon and should be treated with glucose.</p>
<p style="text-indent:-2em;margin-left:4em;">Parenteral:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Weight-based dosing: </i>Infants, Children, and Adolescents: IM, IV, SubQ: 0.02 to 0.03 mg/kg/dose; may repeat every 15 minutes if needed for clinical effect for up to a total of 3 doses; maximum dose: 1 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Product-specific dosing:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Glucagon: Infants, Children, and Adolescents: IM, IV, SubQ:</p>
<p style="text-indent:-2em;margin-left:10em;">&lt;20 kg: 0.5 mg; if no response in 15 minutes, may repeat dose.</p>
<p style="text-indent:-2em;margin-left:10em;">≥20 kg: 1 mg; if no response in 15 minutes, may repeat dose.</p>
<p style="text-indent:-2em;margin-left:8em;">GlucaGen: Infants, Children, and Adolescents: IM, IV, SubQ:</p>
<p style="text-indent:-2em;margin-left:10em;">Weight-directed dosing:</p>
<p style="text-indent:-2em;margin-left:12em;">&lt;25 kg: 0.5 mg; may repeat once if needed.</p>
<p style="text-indent:-2em;margin-left:12em;">≥25 kg: 1 mg; may repeat once if needed.</p>
<p style="text-indent:-2em;margin-left:10em;">Age-directed dosing: <b>Note: </b>Use when weight is unknown.</p>
<p style="text-indent:-2em;margin-left:12em;">Infants and Children &lt;6 years: 0.5 mg; may repeat once if needed.</p>
<p style="text-indent:-2em;margin-left:12em;">Children ≥6 years and Adolescents: 1 mg; may repeat once if needed.</p>
<p style="text-indent:-2em;margin-left:8em;">Gvoke:</p>
<p style="text-indent:-2em;margin-left:10em;">Children 2 to &lt;12 years: SubQ:</p>
<p style="text-indent:-2em;margin-left:12em;">&lt;45 kg: 0.5 mg; if no response after 15 minutes, may administer an additional 0.5 mg dose.</p>
<p style="text-indent:-2em;margin-left:12em;">≥45 kg: 1 mg; if no response after 15 minutes, may administer an additional 1 mg dose.</p>
<p style="text-indent:-2em;margin-left:10em;">Children ≥12 years and Adolescents: SubQ: 1 mg; if no response after 15 minutes, may administer an additional 1 mg dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Intranasal (Baqsimi): Children ≥4 years and Adolescents: 3 mg (1 actuation) intranasally into a single nostril; if no response after 15 minutes, may repeat dose using a new device. <b>Note:</b> Inhalation not necessary.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0184e875-b912-4b46-8ea1-1cdc92615a3e">Hypoglycemia, mild or impending hypoglycemia during illness</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypoglycemia, mild (&lt;70 mg/dL) or impending hypoglycemia during illness (mini-dose regimen):</b> Limited data available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25160667','lexi-content-ref-11315823','lexi-content-ref-29869358','lexi-content-ref-30079506']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25160667','lexi-content-ref-11315823','lexi-content-ref-29869358','lexi-content-ref-30079506'])">Ref</a></span>): <b>Note:</b> These doses are lower than hypoglycemia treatment doses and have been shown to prevent hypoglycemia for several hours during mild hypoglycemia or impending hypoglycemia-associated illness (eg, gastroenteritis, nausea/vomiting) and/or poor oral carbohydrate intake.</p>
<p style="text-indent:-2em;margin-left:4em;">Initial dose:</p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children ≤2 years: SubQ: 0.02 mg.</p>
<p style="text-indent:-2em;margin-left:6em;">Children &gt;2 years and Adolescents ≤15 years: SubQ: 0.01 mg per year of age.</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents &gt;15 years: SubQ: 0.15 mg.</p>
<p style="text-indent:-2em;margin-left:4em;">Subsequent dose: SubQ: If initial dose fails to increase glucose after 30 minutes, may give an additional dose that is twice the initial dose.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8b597bee-38b4-4f8d-a59f-a1484390de69">Anaphylaxis in patients on beta-blocker therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anaphylaxis (refractory to epinephrine) in patients on beta-blocker therapy:</b> Limited data available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25466802','lexi-content-ref-31871244','lexi-content-ref-22211074']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25466802','lexi-content-ref-31871244','lexi-content-ref-22211074'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IV:</p>
<p style="text-indent:-2em;margin-left:6em;">Initial: 0.02 to 0.03 mg/kg slow IV; maximum dose: 1 mg/dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Continuous infusion: Follow initial dose with a continuous infusion of 5 to 15 <b>mcg/minute</b>; titrate to effect.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c8904a63-c527-4b99-9aed-e3fd8b354766">Beta-blocker or calcium channel blocker toxicity/overdose</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Beta-blocker or calcium channel blocker toxicity/overdose:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children:</p>
<p style="text-indent:-2em;margin-left:6em;">Loading dose: IV: 0.05 mg/kg as a single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244','lexi-content-ref-19687715','lexi-content-ref-Nelson.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244','lexi-content-ref-19687715','lexi-content-ref-Nelson.1'])">Ref</a></span>); if no response, may repeat dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Nelson.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Nelson.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Continuous IV infusion: 0.05 to 0.1 mg/kg/<b>hour</b>; titrate to effect (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19687715']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19687715'])">Ref</a></span>); usual adolescent dose: 1 to 5 mg/<b>hour</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20956230']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20956230'])">Ref</a></span>); some experts recommend initiating the infusion at the "response dose" (cumulative loading dose) per hour (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Nelson.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Nelson.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Loading dose: IV: 5 to 10 mg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20956230']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20956230'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Continuous IV infusion: 1 to 5 mg/<b>hour</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20956230']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20956230'])">Ref</a></span>); some experts recommend initiating the infusion at the "response dose" (cumulative loading dose) per hour (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Nelson.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Nelson.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="365760c5-041d-4da4-bb46-7f70860ee148">Esophageal food impaction, esophageal relaxation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Esophageal </b>
<b>food impaction, esophageal relaxation: </b>Limited data available, efficacy results variable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21628009','lexi-content-ref-30918584']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21628009','lexi-content-ref-30918584'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents: IV: 1 mg once prior to endoscopic intervention; may repeat once within 15 to 30 minutes if needed and no adverse effects observed with first dose. <b>Note:</b> Glucagon administration should not delay endoscopic removal of foreign body when necessary.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51112191"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51112192"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F176451"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse drug reactions reported for injection use unless otherwise noted.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (intranasal, IV: 26% to 30%), vomiting (intranasal, IV: 15% to 16%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (intranasal, IV: 5% to 18%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Upper respiratory system symptoms (intranasal: including cough, epistaxis, nasal congestion, nasal discomfort, sneezing, throat irritation: 12%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Pain at injection site (1%), swelling at injection site (7%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined (any route of administration):</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension, hypotension (up to 2 hours after GI procedures), tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pallor, pruritus (including ears), pruritus of nose, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperglycemia</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, diarrhea, dysgeusia</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylactic shock, hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Discomfort at injection site, erythema at injection site, injection site reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Altered sense of smell (intranasal), dizziness, drowsiness</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Asthenia</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Eye pruritus, eye redness, watery eyes</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Rhinorrhea</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing (any indication): Dermatologic: Necrolytic migratory erythema</p></div>
<div class="block coi drugH1Div" id="F176465"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Known hypersensitivity to glucagon or any component of the formulation (injection contains lactose); pheochromocytoma; insulinoma; use of injection as a diagnostic aid in patients with glucagonoma.</p></div>
<div class="block war drugH1Div" id="F176448"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Allergic reactions including skin rash and anaphylactic shock (with hypotension and respiratory difficulties) have been reported; reactions have generally been associated with endoscopic patients.</p>
<p style="text-indent:-2em;margin-left:4em;">• Necrolytic migratory erythema: Necrolytic migratory erythema (NME), a skin rash associated with glucagonomas (glucagon-producing tumors) and characterized by scaly, pruritic, erythematous plaques, bullae, and erosions, has been reported (rarely) following continuous glucagon infusion. Rash may occur on face, groin, perineum, and legs or may be more widespread; rash generally resolves with discontinuation of treatment. Consider the risks versus benefits of continuing the glucagon infusion if NME occurs.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Adrenal insufficiency: Use with caution in patients with adrenal insufficiency; hepatic glycogen levels may be inadequate for glucagon to effectively increase blood glucose.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiac disease: Use with caution in patients with cardiac disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Chronic hypoglycemia: Use with caution in patients with chronic hypoglycemia; hepatic glycogen levels may be inadequate for glucagon to effectively increase blood glucose.</p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes: Use caution if using as diagnostic aid in patients with diabetes on insulin; may cause hyperglycemia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Glucagonoma: Use with caution in patients with glucagonoma; may cause secondary hypoglycemia. The use of injectable glucagon as a diagnostic aid is contraindicated in patients with this condition.</p>
<p style="text-indent:-2em;margin-left:4em;">• Insulinoma: Exogenous glucagon may cause an initial rise in blood glucose followed by rebound hypoglycemia. The use of glucagon is contraindicated in patients with this condition.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pheochromocytoma: Exogenous glucagon may cause the release of catecholamines, resulting in an increase in blood pressure. The use of glucagon is contraindicated in patients with this condition.</p>
<p style="text-indent:-2em;margin-left:4em;">• Starvation/fasting: Use caution with prolonged fasting and/or starvation; hepatic glycogen levels may be inadequate for glucagon to effectively increase blood glucose.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Lactose: May contain lactose; avoid administration in hereditary galactose intolerance, congenital lactase deficiency, or glucose-galactose malabsorption.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Insulin or sulfonylurea overdose: Patients with hypoglycemia should immediately be treated with dextrose. If IV access cannot be established or if dextrose is not available, glucagon may be considered as alternative acute treatment until dextrose can be administered.</p>
<p style="text-indent:-2em;margin-left:4em;">• Secondary hypoglycemia: Supplemental carbohydrates should be given to patients who respond to glucagon for severe hypoglycemia to prevent secondary hypoglycemia.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878473"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Glucagon is only effective if sufficient glycogen stores are present; patients with inadequate storage (eg, starvation, adrenal insufficiency, chronic hypoglycemia) should be treated with glucose.</p></div>
<div class="block foc drugH1Div" id="F176459"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Kit, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Powder, Nasal [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Baqsimi One Pack: 3 mg/dose (1 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Baqsimi Two Pack: 3 mg/dose (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Subcutaneous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Gvoke Kit: 1 mg/0.2 mL (0.2 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Auto-injector, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Gvoke HypoPen 1-Pack: 0.5 mg/0.1 mL (0.1 mL); 1 mg/0.2 mL (0.2 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Gvoke HypoPen 2-Pack: 0.5 mg/0.1 mL (0.1 mL); 1 mg/0.2 mL (0.2 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Subcutaneous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Gvoke PFS: 0.5 mg/0.1 mL (0.1 mL); 1 mg/0.2 mL (0.2 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">GlucaGen Diagnostic: 1 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">GlucaGen HypoKit: 1 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 mg (1 ea); 1 mg/mL (1 ea)</p></div>
<div class="block geq drugH1Div" id="F176444"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F2524623"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Powder</b> (Baqsimi One Pack Nasal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3 mg/dose (per each): $336.96</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Powder</b> (Baqsimi Two Pack Nasal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3 mg/dose (per each): $336.96</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Gvoke Kit Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg/0.2 mL (per 0.2 mL): $368.21</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (GlucaGen Diagnostic Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg (per each): $205.92</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (GlucaGen HypoKit Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg (per each): $369.24</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Glucagon HCl (Diagnostic) Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg (per each): $194.40 - $265.98</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Auto-injector</b> (Gvoke HypoPen 1-Pack Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5MG/0.1ML (per 0.1 mL): $368.21</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg/0.2 mL (per 0.2 mL): $368.21</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Auto-injector</b> (Gvoke HypoPen 2-Pack Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5MG/0.1ML (per 0.1 mL): $368.21</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg/0.2 mL (per 0.2 mL): $368.21</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Prefilled Syringe</b> (Gvoke PFS Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5MG/0.1ML (per 0.1 mL): $368.21</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg/0.2 mL (per 0.2 mL): $368.21</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867059"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Powder, Nasal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Baqsimi: 3 mg/dose (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">GlucaGen: 1 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">GlucaGen HypoKit: 1 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 mg (1 mL)</p></div>
<div class="block adm drugH1Div" id="F176462"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> For the treatment of hypoglycemia, administer fast-acting and long-acting oral carbohydrates to patient as soon as possible after response to glucagon treatment. If patient is unconscious, place in lateral recumbent position to prevent choking when consciousness returns.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IM:</b> For treatment of hypoglycemia, may administer reconstituted solution for injection as an IM injection in the upper arms, thighs, or buttocks. For use as a diagnostic aid for radiologic examinations, may administer IM; for examination of the colon, administer ~10 minutes prior to procedure. After the diagnostic procedure, administer oral carbohydrates to patients who have been fasting, if this is compatible with the diagnostic procedure applied.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Intranasal:</b> Insert the tip of the intranasal device into one nostril and fully depress plunger until the green line is no longer visible. Inhalation of the dose is not necessary. Do not reuse the device after administration.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Rapid injection may be associated with increased nausea and vomiting.</p>
<p style="text-indent:-2em;margin-left:4em;">Anaphylaxis (refractory to epinephrine) in patients on beta-blocker therapy: Administer IV bolus over 5 minutes; continuous infusions may be used (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26505932']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26505932'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Beta-blocker/calcium channel blocker toxicity: Administer IV bolus over 3 to 5 minutes; continuous infusions may be used. Ensure adequate supply available to continue therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20956228']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20956228'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Diagnostic aid for radiologic examinations: May administer IV over 1 minute. After the diagnostic procedure, administer oral carbohydrates to patients who have been fasting, if this is compatible with the diagnostic procedure applied. Bolus IV doses &gt;1 mg are not recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">Hypoglycemia: May administer IV.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Subcutaneous:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Injection, powder for reconstitution: For treatment of hypoglycemia, may administer reconstituted solution in the upper arms, thighs, or buttocks.</p>
<p style="text-indent:-2em;margin-left:4em;">Injection, solution (Gvoke): Administer in the lower abdomen, outer thigh, or outer upper arm; inject rapidly to reduce injection-site pain.</p></div>
<div class="block admp drugH1Div" id="F52612924"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypoglycemia: Note:</b> Administer fast-acting and long-acting oral carbohydrates to patient as soon as possible after response to treatment. If patient is unconscious, place patient on side to prevent choking if vomiting occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">Parenteral:</p>
<p style="text-indent:-2em;margin-left:6em;">Vial: May administer IV or as IM or SUBQ injection in the upper arms, thighs, or buttocks.</p>
<p style="text-indent:-2em;margin-left:8em;">Mini-dose regimen: Following reconstitution of 1 mg/mL solution, inject glucagon SUBQ using an insulin syringe (U-100); 1 unit on the syringe provides 0.01 mg of glucagon (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11315823','lexi-content-ref-29869358']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11315823','lexi-content-ref-29869358'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Autoinjector/prefilled syringe (Gvoke): For SUBQ use only. Do not open foil package until ready to administer. Administer SUBQ in the lower abdomen, outer thigh, or outer upper arm. Do not reuse the device after administration; a new device should be used for each dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Intranasal: For intranasal use only. Insert the tip of the device into 1 nostril and fully depress plunger until the green line is no longer visible. Inhalation of the dose is not necessary. Do not reuse the device after administration.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Anaphylaxis:</b> Initial dose should be administered over 5 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25466802','lexi-content-ref-22211074']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25466802','lexi-content-ref-22211074'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Beta-blocker/calcium channel blocker toxicity:</b> Initial loading dose (bolus) should be administered over 1 to 5 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Nelson.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Nelson.1'])">Ref</a></span>); may also administer as a continuous IV infusion; ensure adequate supply available to continue therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20956228']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20956228'])">Ref</a></span>).</p></div>
<div class="block uica drugH1Div" id="F14472642"><span class="drugH1">Usual Infusion Concentrations: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IV infusion:</b> 4 mg in 50 mL (concentration: 0.08 mg/mL); some centers may use a higher concentration (eg, 20 mg in 100 mL [concentration 0.2 mg/mL] of D5W) to meet the needs in some patients (eg, beta-blocker or calcium channel blocker overdose).</p></div>
<div class="block use drugH1Div" id="F176460"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Diagnostic aid: Radiologic examinations (injection):</b> As a diagnostic aid during radiologic examinations to temporarily inhibit movement of the GI tract in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypoglycemia:</b>
<b>Note:</b> The American Diabetes Association (ADA) recommends that glucagon be prescribed for all patients with diabetes at increased risk of level 2 hypoglycemia (&lt;54 mg/dL); caregivers, school personnel, or family members of these patients should be trained on when and how to administer glucagon (ADA 2023).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Injection, powder for reconstitution (GlucaGen HypoKit or Glucagon Emergency)</i>: Treatment of severe hypoglycemia in pediatric and adult patients with diabetes.</p>
<p style="text-indent:-2em;margin-left:6em;">Limitations of use: Products not packaged with a syringe and diluent necessary for rapid preparation and administration during an emergency outside of a health care facility are not indicated for the emergency treatment of hypoglycemia.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Injection, solution (Gvoke):</i> Treatment of severe hypoglycemia in adult and pediatric patients (≥2 years of age) with diabetes.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Intranasal:</i> Treatment of severe hypoglycemia in adult and pediatric patients (≥4 years of age) with diabetes.</p></div>
<div class="block off-label drugH1Div" id="F25474760"><span class="drugH1">Use: Off-Label: Adult</span><p>Anaphylaxis; Beta-blocker overdose; Calcium channel blocker overdose; Growth hormone deficiency (alternative diagnostic test)</p></div>
<div class="block cyt drugH1Div" id="F13299406"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F176453"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Anticholinergic Agents: May enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indomethacin: May diminish the therapeutic effect of Glucagon and Glucagon Analogs.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Glucagon and Glucagon Analogs may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F176477"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Glucagon depletes glycogen stores.</p></div>
<div class="block pri drugH1Div" id="F13882222"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Glucagon may be used for the treatment of severe hypoglycemia during pregnancy (Alexopoulos 2019). In general, medications used as antidotes should take into consideration the health and prognosis of the mother; antidotes should be administered to pregnant females if there is a clear indication for use and should not be withheld because of concerns of teratogenicity (Bailey 2003a).</p></div>
<div class="block brc drugH1Div" id="F13882223"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">Glucagon is not absorbed from the GI tract and therefore, it is unlikely adverse effects would occur in a breastfeeding infant.</p></div>
<div class="block dic drugH1Div" id="F176468"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Administer oral carbohydrates to patient as soon as possible after response to treatment.</p></div>
<div class="block mop drugH1Div" id="F176457"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">BP, blood glucose, ECG, heart rate, mentation; signs or symptoms of a hypersensitivity reaction.</p>
<p style="text-indent:-2em;margin-left:2em;">Growth hormone (GH) deficiency: Serum GH levels at baseline (prior to glucagon injection) and every 30 minutes for 4 hours following administration (AACE/ACE [Yuen 2019]; Hamrahian 2016).</p></div>
<div class="block rer drugH1Div" id="F50511144"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Classification of hypoglycemia (ADA 2023):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Level 1: Glucose ≥54 to ≤70 mg/dL; hypoglycemia alert value; initiate fast-acting carbohydrate (eg, glucose) treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">Level 2: Glucose &lt;54 mg/dL; threshold for neuroglycopenic symptoms; requires immediate action.</p>
<p style="text-indent:-2em;margin-left:4em;">Level 3: Hypoglycemia associated with a severe event characterized by altered mental and/or physical status requiring assistance.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Diagnosis of adult growth hormone deficiency (AACE/ACE [Yuen 2019]): Note:</b> Use caution when interpreting growth hormone (GH) levels in patients with hyperglycemia and in patients &gt;70 years of age; diagnostic accuracy of glucagon stimulation in these populations is unknown.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Patients with BMI &lt;25 kg/m<sup>2</sup>, or with BMI 25 to 30 kg/m<sup>2</sup> and high pretest probability:</i> Peak GH levels &lt;3 mcg/L (assay dependent) within 4 hours following glucagon administration confirm the presence of adult growth hormone deficiency.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Patients with BMI &gt;30 kg/m<sup>2</sup>, or with BMI 25 to 30 kg/m<sup>2</sup> and low pretest probability: </i>Peak GH levels &lt;1 mcg/L (assay dependent) within 4 hours following glucagon administration confirm the presence of adult growth hormone deficiency.</p></div>
<div class="block pha drugH1Div" id="F176447"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:-2em;margin-left:2em;">Stimulates adenylate cyclase to produce increased cyclic AMP, which promotes hepatic glycogenolysis and gluconeogenesis, causing a raise in blood glucose levels; antihypoglycemic effect requires preexisting hepatic glycogen stores. Extra hepatic effects of glucagon include relaxation of the smooth muscle of the stomach, duodenum, small bowel, and colon.</p>
<p style="text-indent:-2em;margin-left:2em;">In the setting of beta-blocker and calcium channel blocker toxicity, the glucagon-mediated increase in cyclic AMP increases automaticity at the sinoatrial and atrioventricular nodes. In addition, glucagon improves myocardial contractility and produces peripheral vasodilation (Bailey 2003b).</p></div>
<div class="block phk drugH1Div" id="F176464"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Blood glucose concentrations:</i>
<b>Note:</b> In general, when used for the treatment of hypoglycemia, the time required to correct hypoglycemia (eg, increase blood glucose concentrations by 20 mg/dL) is similar between formulations and routes of administration (~10 to 15 minutes); clinicians should note that the durability of response may result in blood glucose concentrations that continue to rise for &gt;90 minutes (Baqsimi prescribing information 2019; Gvoke prescribing information; Rickels 2016).</p>
<p style="text-indent:-2em;margin-left:6em;">IV: Peak effect: 5 to 20 minutes (GlucaGen prescribing information 2018).</p>
<p style="text-indent:-2em;margin-left:6em;">IM:</p>
<p style="text-indent:-2em;margin-left:8em;">Onset: 10 minutes.</p>
<p style="text-indent:-2em;margin-left:8em;">Peak effect: 30 minutes when used as a diagnostic aid (GlucaGen prescribing information 2018); in patients with type 1 diabetes and insulin-induced hypoglycemia, the peak glucose response was not yet reached during the 90-minute observation window following glucagon administration (Rickels 2016).</p>
<p style="text-indent:-2em;margin-left:6em;">Intranasal:</p>
<p style="text-indent:-2em;margin-left:8em;">Onset: Slightly delayed compared to IM administration; for example, median response time to reach glucose target in adults was 13 minutes (IM) versus 16 minutes (intranasal), but clinical outcomes/resolution of hypoglycemia at 30 minutes did not differ (Rickels 2016).</p>
<p style="text-indent:-2em;margin-left:8em;">Peak effect: Patients with type 1 diabetes:</p>
<p style="text-indent:-2em;margin-left:10em;">Children ≥4 years of age: ~60 minutes (Baqsimi prescribing information 2019).</p>
<p style="text-indent:-2em;margin-left:10em;">Adults: A peak glucose response was not yet reached during the 90-minute observation window following glucagon administration (Baqsimi prescribing information 2019; Rickels 2016).</p>
<p style="text-indent:-2em;margin-left:6em;">SUBQ:</p>
<p style="text-indent:-2em;margin-left:8em;">Onset: ~10 minutes; Gvoke onset is delayed a few minutes compared to Glucagon Emergency, but clinical outcomes/resolution of hypoglycemia at 30 minutes did not differ between SUBQ formulations (Gvoke prescribing information).</p>
<p style="text-indent:-2em;margin-left:8em;">Peak effect: 30 to 45 minutes in healthy patients (GlucaGen prescribing information 2018; Glucagon Emergency prescribing information 2018); in patients with type 1 diabetes and insulin-induced hypoglycemia, the peak glucose response was not yet reached during the 90-minute observation window following glucagon administration (Gvoke prescribing information).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>GI relaxation:</i> IV: 45 seconds; IM: 4 to 10 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Duration:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Blood</i>
<i>glucose concentrations</i>: 60 to 90 minutes (GlucaGen prescribing information 2018); other data suggest glucose elevation may persist &gt;90 minutes following intranasal, IM, or SUBQ administration in patients with type 1 diabetes (Gvoke prescribing information; Rickels 2016).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>GI relaxation:</i> IV: 9 to 25 minutes; IM: 12 to 32 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: Reported values vary significantly: ~0.25 L/kg (Glucagon Emergency); 137 to 2,425 L (Gvoke); 885 L (Baqsimi).</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Primarily hepatic; some inactivation occurring renally and in plasma.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination, plasma:</p>
<p style="text-indent:-2em;margin-left:4em;">IV: 8 to 18 minutes.</p>
<p style="text-indent:-2em;margin-left:4em;">IM (apparent): 26 to 45 minutes.</p>
<p style="text-indent:-2em;margin-left:4em;">Intranasal (apparent): Median:</p>
<p style="text-indent:-2em;margin-left:6em;">Pediatric patients 4 to &lt;17 years: 21 to 31 minutes.</p>
<p style="text-indent:-2em;margin-left:6em;">Adults: ~35 minutes.</p>
<p style="text-indent:-2em;margin-left:4em;">SUBQ: 32 minutes (Gvoke prescribing information; not reported for other formulations).</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma:</p>
<p style="text-indent:-2em;margin-left:4em;">IM: ~10 to 12.5 minutes.</p>
<p style="text-indent:-2em;margin-left:4em;">Intranasal:</p>
<p style="text-indent:-2em;margin-left:6em;">Pediatric patients 4 to &lt;17 years: 15 to 20 minutes.</p>
<p style="text-indent:-2em;margin-left:6em;">Adults: 15 minutes.</p>
<p style="text-indent:-2em;margin-left:4em;">SUBQ:</p>
<p style="text-indent:-2em;margin-left:6em;">Glucagon Emergency: 20 minutes.</p>
<p style="text-indent:-2em;margin-left:6em;">Gvoke:</p>
<p style="text-indent:-2em;margin-left:8em;">Pediatric patients:</p>
<p style="text-indent:-2em;margin-left:10em;">2 to &lt;6 years: 41 minutes.</p>
<p style="text-indent:-2em;margin-left:10em;">6 to &lt;12 years: 34 minutes.</p>
<p style="text-indent:-2em;margin-left:10em;">12 to &lt;18 years: 51 minutes.</p>
<p style="text-indent:-2em;margin-left:8em;">Adults: 50 minutes.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F176469"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Glucagon</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Glucagen</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Glucagen</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Ogluo</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Glucagen | Glucagon lilly</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Glucagon Dci</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Glucagon lilly | Ogluo</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Glucagon novo nordisk</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Glucagon</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Ogluo</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Glucagon</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Glucagen</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Glucagon</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Glucagon</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Glucagen</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Glucagon</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Glucagon</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Glucagen | Glucagon lilly</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Glucagon</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Baqsimi | Gvoke hypopen | Gvoke kit | Gvoke pfs</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Glucagen</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Baqsimi | GlucaGen</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Glucagon</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Glucagon novo nordisk</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Glucagon</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Glucagon</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Glucagon</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Glucagen</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-29869358">
<a name="29869358"></a>Abraham MB, Jones TW, Naranjo D, et al. ISPAD clinical practice consensus guidelines 2018: Assessment and management of hypoglycemia in children and adolescents with diabetes. <i>Pediatr Diabetes</i>. 2018;19(suppl 27):178-192.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glucagon-drug-information/abstract-text/29869358/pubmed" id="29869358" target="_blank">29869358</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31087027">
<a name="31087027"></a>Alexopoulos AS, Blair R, Peters AL. Management of preexisting diabetes in pregnancy: a review. <i>JAMA</i>. 2019;321(18):1811-1819. doi:10.1001/jama.2019.4981<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glucagon-drug-information/abstract-text/31087027/pubmed" id="31087027" target="_blank">31087027</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ADA.1">
<a name="ADA.1"></a>American Diabetes Association (ADA). Standards of medical care in diabetes–2021.<i> Diabetes Care.</i> 2021;44(suppl 1):S1-S232. https://care.diabetesjournals.org/content/44/Supplement_1. Accessed January 13, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ADA.2">
<a name="ADA.2"></a>American Diabetes Association (ADA). Standards of care in diabetes–2023. <i>Diabetes Care</i>. 2023;46(suppl 1):S1-S291. https://diabetesjournals.org/care/issue/46/Supplement_1. Accessed January 4, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19687715">
<a name="19687715"></a>Arroyo AM, Kao LW. Calcium channel blocker toxicity. <i>Pediatr Emerg Care</i>. 2009;25(8):532-540.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glucagon-drug-information/abstract-text/19687715/pubmed" id="19687715" target="_blank">19687715</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21628009">
<a name="21628009"></a>ASGE Standards of Practice Committee, Ikenberry SO, Jue TL, et al. Management of ingested foreign bodies and food impactions. <i>Gastrointest Endosc</i>. 2011;73(6):1085‐1091.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glucagon-drug-information/abstract-text/21628009/pubmed" id="21628009" target="_blank">21628009</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10685981">
<a name="10685981"></a>Aynsley-Green A, Hussain K, Hall J, et al. Practical Management of Hyperinsulinism in Infancy. <i>Arch Dis Child Fetal Neonatal Ed</i>. 2000;82(2):98-107.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glucagon-drug-information/abstract-text/10685981/pubmed" id="10685981" target="_blank">10685981</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12769509">
<a name="12769509"></a>Bailey B. Are there teratogenic risks associated with antidotes used in the acute management of poisoned pregnant women? <i>Birth Defects Res A Clin Mol Teratol</i>. 2003a;67(2):133-140. doi:10.1002/bdra.10007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glucagon-drug-information/abstract-text/12769509/pubmed" id="12769509" target="_blank">12769509</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14514004">
<a name="14514004"></a>Bailey B. Glucagon in beta-blocker and calcium channel blocker overdoses: a systematic review. <i>J Toxicol Clin Toxicol</i>. 2003b;41(5):595-602. doi:10.1081/clt-120023761<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glucagon-drug-information/abstract-text/14514004/pubmed" id="14514004" target="_blank">14514004</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Baqsimi.1">
<a name="Baqsimi.1"></a>Baqsimi (glucagon) [prescribing information]. Indianapolis, IN: Lilly USA LLC; August 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Barrueto.1">
<a name="Barrueto.1"></a>Barrueto F. Calcium channel blocker poisoning. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 28, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25466802">
<a name="25466802"></a>Campbell RL, Li JT, Nicklas RA, Sadosty AT; Members of the Joint Task Force; Practice Parameter Workgroup. Emergency department diagnosis and treatment of anaphylaxis: a practice parameter. <i>Ann Allergy Asthma Immunol</i>. 2014;113(6):599-608.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glucagon-drug-information/abstract-text/25466802/pubmed" id="25466802" target="_blank">25466802</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3196055">
<a name="3196055"></a>Carter PE, Lloyd DJ, Duffty P. Glucagon for hypoglycaemia in infants small for gestational age. <i>Arch Dis Child</i>. 1988;63(10):1264-1266.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glucagon-drug-information/abstract-text/3196055/pubmed" id="3196055" target="_blank">3196055</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12509583">
<a name="12509583"></a>Charsha DS, McKinley PS, Whitfield JM. Glucagon infusion for treatment of hypoglycemia: efficacy and safety in sick, preterm infants. <i>Pediatrics</i>. 2003;111(1):220-221.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glucagon-drug-information/abstract-text/12509583/pubmed" id="12509583" target="_blank">12509583</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22211074">
<a name="22211074"></a>Cheng A. Emergency treatment of anaphylaxis in infants and children. <i>Paediatr Child Health</i>. 2011;16(1):35-40.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glucagon-drug-information/abstract-text/22211074/pubmed" id="22211074" target="_blank">22211074</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30093549">
<a name="30093549"></a>Chiang JL, Maahs DM, Garvey KC, et al. Type 1 diabetes in children and adolescents: a position statement by the American Diabetes Association. <i>Diabetes Care</i>. 2018;41(9):2026-2044.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glucagon-drug-information/abstract-text/30093549/pubmed" id="30093549" target="_blank">30093549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25160667">
<a name="25160667"></a>Chung ST, Haymond MW. Minimizing morbidity of hypoglycemia in diabetes: a review of mini-dose glucagon. <i>J Diabetes Sci Technol</i>. 2015;9(1):44-51.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glucagon-drug-information/abstract-text/25160667/pubmed" id="25160667" target="_blank">25160667</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28669553">
<a name="28669553"></a>Dart RC, Goldfrank LR, Erstad BL, et al. Expert consensus guidelines for stocking of antidotes in hospitals that provide emergency care. <i>Ann Emerg Med</i>. 2018;71(3):314-325.e1. doi:10.1016/j.annemergmed.2017.05.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glucagon-drug-information/abstract-text/28669553/pubmed" id="28669553" target="_blank">28669553</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25210883">
<a name="25210883"></a>Dichtel LE, Yuen KC, Bredella MA, et al. Overweight/Obese adults with pituitary disorders require lower peak growth hormone cutoff values on glucagon stimulation testing to avoid overdiagnosis of growth hormone deficiency. <i>J Clin Endocrinol Metab</i>. 2014;99(12):4712-4719. doi:10.1210/jc.2014-2830<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glucagon-drug-information/abstract-text/25210883/pubmed" id="25210883" target="_blank">25210883</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26129876">
<a name="26129876"></a>Diri H, Karaca Z, Simsek Y, et al. Can a glucagon stimulation test characterized by lower GH cut-off value be used for the diagnosis of growth hormone deficiency in adults? <i>Pituitary</i>. 2015;18(6):884-892. doi:10.1007/s11102-015-0666-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glucagon-drug-information/abstract-text/26129876/pubmed" id="26129876" target="_blank">26129876</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20956217">
<a name="20956217"></a>Field JM, Hazinski MF, Sayre MR, et al. Part 1: executive summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation</i>. 2010;122(18)(suppl 3):S640-S656.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glucagon-drug-information/abstract-text/20956217/pubmed" id="20956217" target="_blank">20956217</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30918584">
<a name="30918584"></a>Fung BM, Sweetser S, Wong Kee Song LM, Tabibian JH. Foreign object ingestion and esophageal food impaction: An update and review on endoscopic management. <i>World J Gastrointest Endosc</i>. 2019;11(3):174‐192.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glucagon-drug-information/abstract-text/30918584/pubmed" id="30918584" target="_blank">30918584</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30086874">
<a name="30086874"></a>Galcheva S, Al-Khawaga S, Hussain K. Diagnosis and management of hyperinsulinaemic hypoglycaemia. <i>Best Pract Res Clin Endocrinol Metab</i>. 2018;32(4):551-573.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glucagon-drug-information/abstract-text/30086874/pubmed" id="30086874" target="_blank">30086874</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-GlucaGen.1">
<a name="GlucaGen.1"></a>GlucaGen (glucagon) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; July 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-GlucaGen.2">
<a name="GlucaGen.2"></a>GlucaGen HypoKit and Diagnostic Kit (glucagon) [prescribing information]. Plainsboro, NJ: Novo Nordisk; March 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Glucagon.1">
<a name="Glucagon.1"></a>Glucagon Emergency Kit [prescribing information]. Lake Zurich, IL: Fresenius Kabi; August 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Glucagon.2">
<a name="Glucagon.2"></a>Glucagon for injection [prescribing information]. Lake Zurich, IL: Fresenius Kabi; July 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Glucagon.3">
<a name="Glucagon.3"></a>Glucagon injection [prescribing information]. Lake Zurich, IL: Fresenius Kabi; January 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Glucagon.4">
<a name="Glucagon.4"></a>Glucagon injection [prescribing information]. Lake Zurich, IL: Fresenius Kabi; August 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gvoke.1">
<a name="Gvoke.1"></a>Gvoke (glucagon) [prescribing information]. Chicago, IL: Xeris Pharmaceuticals Inc; August 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26897383">
<a name="26897383"></a>Hamrahian AH, Yuen KC, Gordon MB, Pulaski-Liebert KJ, Bena J, Biller BM. Revised GH and cortisol cut-points for the glucagon stimulation test in the evaluation of GH and hypothalamic-pituitary-adrenal axes in adults: results from a prospective randomized multicenter study. <i>Pituitary</i>. 2016;19(3):332-341. doi:10.1007/s11102-016-0712-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glucagon-drug-information/abstract-text/26897383/pubmed" id="26897383" target="_blank">26897383</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8466259">
<a name="8466259"></a>Hawdon JM, Aynsley-Green A, Ward Platt MP. Neonatal Blood Glucose Concentrations: Metabolic Effects of Intravenous Glucagon and Intragastric Medium Chain Triglyceride. <i>Arch Dis Child</i>. 1993;68(3 Spec No):255-261.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glucagon-drug-information/abstract-text/8466259/pubmed" id="8466259" target="_blank">8466259</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11315823">
<a name="11315823"></a>Haymond MW, Schreiner B. Mini-dose glucagon rescue for hypoglycemia in children with type 1 diabetes. <i>Diabetes Care</i>. 2001;24(4):643-645.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glucagon-drug-information/abstract-text/11315823/pubmed" id="11315823" target="_blank">11315823</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16496493">
<a name="16496493"></a>Holger JS, Engebretsen KM, Obetz CL, et al. A Comparison of Vasopressin and Glucagon in Beta-Blocker Induced Toxicity. <i>Clin Toxicol (Phila)</i>. 2006;44(1):45-51. doi:10.1080/15563650500394795<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glucagon-drug-information/abstract-text/16496493/pubmed" id="16496493" target="_blank">16496493</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14711860">
<a name="14711860"></a>Hussain K, Aynsley-Green A. Hyperinsulinaemic Hypoglycaemia in Preterm Neonates. <i>Arch Dis Child Fetal Neonatal Ed</i>. 2004;89(1):65-67.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glucagon-drug-information/abstract-text/14711860/pubmed" id="14711860" target="_blank">14711860</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19193661">
<a name="19193661"></a>Kapoor RR, Flanagan SE, James C, et al. Hyperinsulinaemic Hypoglycaemia. <i>Arch Dis Child</i>. 2009;94(6):450-457.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glucagon-drug-information/abstract-text/19193661/pubmed" id="19193661" target="_blank">19193661</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20956230">
<a name="20956230"></a>Kleinman ME, Chameides L, Schexnayder SM, et al. Part 14: pediatric advanced life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation</i>. 2010;122(18)(suppl 3):S876-S908.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glucagon-drug-information/abstract-text/20956230/pubmed" id="20956230" target="_blank">20956230</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30412709">
<a name="30412709"></a>Kusumoto FM, Schoenfeld MH, Barrett C, et al. 2018 ACC/AHA/HRS Guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines and the Heart Rhythm Society. <i>J Am Coll Cardiol</i>. 2018. pii: S0735-1097(18)38985-X. doi:10.1016/j.jacc.2018.10.044<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glucagon-drug-information/abstract-text/30412709/pubmed" id="30412709" target="_blank">30412709</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30079506">
<a name="30079506"></a>Laffel LM, Limbert C, Phelan H, Virmani A, Wood J, Hofer SE. ISPAD clinical practice consensus guidelines 2018: sick day management in children and adolescents with diabetes. <i>Pediatr Diabetes</i>. 2018;19(suppl 27):193-204.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glucagon-drug-information/abstract-text/30079506/pubmed" id="30079506" target="_blank">30079506</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26505932">
<a name="26505932"></a>Lieberman P, Nicklas RA, Randolph C, et al. Anaphylaxis--a practice parameter update 2015. <i>Ann Allergy Asthma Immunol.</i> 2015;115(5):341-384. doi:10.1016/j.anai.2015.07.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glucagon-drug-information/abstract-text/26505932/pubmed" id="26505932" target="_blank">26505932</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9674488">
<a name="9674488"></a>Love JN, Sachdeva DK, Bessman ES, et al. A Potential Role for Glucagon in the Treatment of Drug-Induced Symptomatic Bradycardia. <i>Chest</i>. 1998;114(1):323-326.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glucagon-drug-information/abstract-text/9674488/pubmed" id="9674488" target="_blank">9674488</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3314727">
<a name="3314727"></a>Mehta A, Wootton R, Cheng KN, et al. Effect of Diazoxide or Glucagon on Hepatic Glucose Production Rate During Extreme Neonatal Hypoglycaemia.<i> Arch Dis Child</i>. 1987;62(9):924-930.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glucagon-drug-information/abstract-text/3314727/pubmed" id="3314727" target="_blank">3314727</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12361445">
<a name="12361445"></a>Miralles RE, Lodha A, Perlman M, et al. Experience With Intravenous Glucagon Infusions as a Treatment for Resistant Neonatal Hypoglycemia. <i>Arch Pediatr Adolesc Med</i>. 2002;156(10):999-1004.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glucagon-drug-information/abstract-text/12361445/pubmed" id="12361445" target="_blank">12361445</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12628894">
<a name="12628894"></a>Mokhlesi B, Leikin JB, Murray P, et al. Adult Toxicology in Critical Care: Part II: Specific Poisonings. <i>Chest</i>. 2003;123(3):897-922.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glucagon-drug-information/abstract-text/12628894/pubmed" id="12628894" target="_blank">12628894</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nelson.1">
<a name="Nelson.1"></a>Nelson LS, Howland, MA, Lewin NA, et al, eds. <i>Goldfrank's Toxicologic Emergencies</i>. 11th ed. McGraw-Hill Education; 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26681725">
<a name="26681725"></a>Rickels MR, Ruedy KJ, Foster NC, et al; T1D Exchange Intranasal Glucagon Investigators. Intranasal glucagon for treatment of insulin-induced hypoglycemia in adults with type 1 diabetes: a randomized crossover noninferiority study. <i>Diabetes Care</i>. 2016;39(2):264-270. doi: 10.2337/dc15-1498.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glucagon-drug-information/abstract-text/26681725/pubmed" id="26681725" target="_blank">26681725</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27915035">
<a name="27915035"></a>Shah P, Rahman SA, Demirbilek H, Güemes M, Hussain K. Hyperinsulinaemic hypoglycaemia in children and adults. <i>Lancet Diabetes Endocrinol</i>. 2017;5(9):729-742.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glucagon-drug-information/abstract-text/27915035/pubmed" id="27915035" target="_blank">27915035</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31871244">
<a name="31871244"></a>Shenoi RP, Timm N; Committee on Drugs; Committee on Pediatric Emergency Medicine. Drugs Used to Treat Pediatric Emergencies. <i>Pediatrics</i>. 2020;145(1):e20193450.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glucagon-drug-information/abstract-text/31871244/pubmed" id="31871244" target="_blank">31871244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16990629">
<a name="16990629"></a>Shepherd G. Treatment of poisoning caused by beta-adrenergic and calcium-channel blockers [published correction appears in <i>J Health Syst Pharm</i>. 2008;65(17):1592]. <i>Am J Health Syst Pharm</i>. 2006;63(19):1828-1835. doi:10.2146/ajhp060041<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glucagon-drug-information/abstract-text/16990629/pubmed" id="16990629" target="_blank">16990629</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25957977">
<a name="25957977"></a>Thornton PS, Stanley CA, De Leon DD, et al. Recommendations from the Pediatric Endocrine Society for Evaluation and Management of Persistent Hypoglycemia in Neonates, Infants, and Children. <i>J Pediatr</i>. 2015;167(2):238-245.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glucagon-drug-information/abstract-text/25957977/pubmed" id="25957977" target="_blank">25957977</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9468179">
<a name="9468179"></a>Trujillo MH, Guerrero J, Fragachan C, et al. Pharmacologic Antidotes in Critical Care Medicine: A Practical Guide for Drug Administration. <i>Crit Care Med</i>. 1998;26(2):377-391. doi:10.1097/00003246-199802000-00044<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glucagon-drug-information/abstract-text/9468179/pubmed" id="9468179" target="_blank">9468179</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20956228">
<a name="20956228"></a>Vanden Hoek TL, Morrison LJ, Shuster M, et al. Part 12: cardiac arrest in special situations: 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care [published corrections appear in <i>Circulation</i>. 2011;123(6):e239; <i>Circulation</i>. 2011;124(15):e405]. <i>Circulation</i>. 2010;122(18)(suppl 3):S829-S861. doi:10.1161/CIRCULATIONAHA.110.971069<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glucagon-drug-information/abstract-text/20956228/pubmed" id="20956228" target="_blank">20956228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15906457">
<a name="15906457"></a>Wax PM, Erdman AR, Chyka PA, et al. Beta-Blocker Ingestion: An Evidence-Based Consensus Guideline for Out-of-Hospital Management. <i>Clin Toxicol (Phila)</i>. 2005;43(3):131-146.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glucagon-drug-information/abstract-text/15906457/pubmed" id="15906457" target="_blank">15906457</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28804205">
<a name="28804205"></a>Yorifuji T, Horikawa R, Hasegawa T, et al. Clinical practice guidelines for congenital hyperinsulinism. <i>Clin Pediatr Endocrinol</i>. 2017;26(3):127-152.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glucagon-drug-information/abstract-text/28804205/pubmed" id="28804205" target="_blank">28804205</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22806554">
<a name="22806554"></a>Yuen KC, Biller BM, Katznelson L, et al. Clinical characteristics, timing of peak responses and safety aspects of two dosing regimens of the glucagon stimulation test in evaluating growth hormone and cortisol secretion in adults. <i>Pituitary</i>. 2013;16(2):220-230. doi:10.1007/s11102-012-0407-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glucagon-drug-information/abstract-text/22806554/pubmed" id="22806554" target="_blank">22806554</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31760824">
<a name="31760824"></a>Yuen KCJ, Biller BMK, Radovick S, et al. American Association Of Clinical Endocrinologists and American College of Endocrinology guidelines for management of growth hormone deficiency in adults and patients transitioning from pediatric to adult care. <i>Endocr Pract.</i> 2019;25(11):1191-1232. doi:10.4158/GL-2019-0405<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glucagon-drug-information/abstract-text/31760824/pubmed" id="31760824" target="_blank">31760824</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8493 Version 303.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
